Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03670069Phase 1Terminated

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

NCT03063632Phase 2Completed

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Showing all 2 trials

Research Network

Activity Timeline